Summary
Cagrilintide is a long-acting synthetic analogue of amylin, a 37-amino-acid hormone released alongside insulin that slows stomach emptying and signals fullness. Developed by Novo Nordisk, it is mostly studied in combination with semaglutide under the name CagriSema. It is an investigational drug and not yet licensed anywhere.
What it targets
Cagrilintide acts on amylin and calcitonin receptors. Two phase 3 trials of the cagrilintide-semaglutide combination reported mean body-weight reductions of about 20% in adults with obesity without diabetes (n=3,417) and about 14% in adults with obesity and type 2 diabetes (n=1,206) over 68 weeks, against about 3% with placebo; gastrointestinal adverse events were common but mostly mild to moderate. In diet-induced obese rats, combining cagrilintide with retatrutide lowered weight and food intake more than either alone. The phase 3 data are for the combination, not cagrilintide by itself.
Clinical Research
Suppliers stocking Cagrilintide
10 of the 30 listed suppliers. Each row opens its full listing.